Free Trial
NASDAQ:ZURA

Zura Bio Q1 2024 Earnings Report

Zura Bio logo
$1.01 -0.01 (-0.49%)
Closing price 04:00 PM Eastern
Extended Trading
$1.03 +0.02 (+1.97%)
As of 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A

Zura Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zura Bio Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Zura Bio's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Zura Bio Earnings Headlines

Dalio heeds Buffett’s warning… [$319 million stake in gold]
Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts. I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks.
What is HC Wainwright's Forecast for Zura Bio Q2 Earnings?
What is HC Wainwright's Forecast for Zura Bio Q1 Earnings?
See More Zura Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email.

About Zura Bio

Zura Bio (NASDAQ:ZURA), a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

View Zura Bio Profile

More Earnings Resources from MarketBeat